ASTRAZENECA Company Profile

What is the competitive landscape for ASTRAZENECA

ASTRAZENECA has ninety-two approved drugs.

There are ninety-five US patents protecting ASTRAZENECA drugs. There is one tentative approval on ASTRAZENECA drugs.

There are one thousand nine hundred and ninety-two patent family members on ASTRAZENECA drugs in sixty-five countries and three hundred and eighty-nine supplementary protection certificates in twenty-one countries.

Summary for ASTRAZENECA

International Patents:	1992
US Patents:	95
Tradenames:	64
Ingredients:	60
NDAs:	92
Patent Litigation for ASTRAZENECA:	See patent lawsuits for ASTRAZENECA
PTAB Cases with ASTRAZENECA as patent owner:	See PTAB cases with ASTRAZENECA as patent owner

Drugs and US Patents for ASTRAZENECA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No	8,808,750
Astrazeneca	CALQUENCE	acalabrutinib	CAPSULE;ORAL	210259-001	Oct 31, 2017		RX	Yes	Yes
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No	9,884,092*PED				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-004	May 2, 2019		DISCN	Yes	No	9,616,028*PED				Y
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-001	Jul 31, 2009		DISCN	Yes	No	7,951,400		Y
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-002	Jul 21, 2006	AB	RX	Yes	Yes
Astrazeneca	RHINOCORT	budesonide	AEROSOL, METERED;NASAL	020233-001	Feb 14, 1994		DISCN	No	No

Expired US Patents for ASTRAZENECA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	BRILINTA	ticagrelor	TABLET;ORAL	022433-002	Sep 3, 2015	6,525,060
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558-001	Aug 17, 2017	9,169,235
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017	6,956,026
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-005	Jul 28, 2017	9,198,925
Astrazeneca Ab	QTERN	dapagliflozin; saxagliptin hydrochloride	TABLET;ORAL	209091-002	May 2, 2019	9,198,925
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-004	May 2, 2019	6,936,590
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017	6,936,590

Paragraph IV (Patent) Challenges for ASTRAZENECA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe		2014-06-11
	HydrochlorideExtended-release Tablets	2.5 mg/1000 mg		2018-10-29
	Nasal Spray	0.032 mg (32 mcg)/spray		2007-05-14
	Delayed-release for Oral Suspension	2.5 mg and 5 mg		2018-09-24
	Injection	50 mg/mL, 2.5 mL and 5 mL syringe		2009-10-01
	Inhalation Suspension	1 mg/2 mL		2010-05-28
	Delayed-release Tablets	20 mg		2012-03-30
	Tablets	60 mg		2015-09-30
	Tablets	500 mcg		2015-03-02
	Extended-release Tablets	5 mg/500 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg		2013-07-31
	Tablets	2.5 mg and 5 mg		2013-07-31
	Delayed-release	20 mg and 40 mg		2005-08-05
	For Injection	20 mg/vial and 40 mg/vial		2009-11-23
	Inhalation Suspension	0.25 mg/2 mL and 0.5 mg/2 mL		2005-09-15
	Delayed-release Capsules	20 mg		2007-03-19
	Tablets	90 mg		2015-07-20
	Tablets	5 mg, 10 mg, 20 mg and 40 mg		2007-08-13

International Patents for ASTRAZENECA Drugs

Country	Patent Number	Estimated Expiration
South Korea	101422619
Hong Kong	1251457
Taiwan	200609002
Serbia	60190
South Korea	20100101077
Argentina	045738
Eurasian Patent Organization	201992270

Supplementary Protection Certificates for ASTRAZENECA Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
0823900	C300429	Netherlands		PRODUCT NAME: GEFITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/526/00156154 2009020624
1848414	C 2016 026	Romania		PRODUCT NAME: OSIMERTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1086; DATE OF NATIONAL AUTHORISATION: 20160202; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1086; DATE OF FIRST AUTHORISATION IN EEA: 20160202
1968948	2190048-5	Sweden		PRODUCT NAME: SELUMETINIB HYDROGEN SULFATE, INCLUDING ANY SOLVATES AND ANHYDROUS FORMS THEREOF; REG. NO/DATE: EU/1/21/1552 20210619
0290047	97C0108	Belgium		PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
0186405	SPC/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
1482932	SPC/GB19/007	United Kingdom		PRODUCT NAME: BINIMETINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/18/1315/001-002 20180920

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Astral
• Astrazeneca
• Astrazeneca Ab
• Astrazeneca Lp

AstraZeneca: Market Position, Strengths & Strategic Insights

Last updated: February 26, 2026

What is AstraZeneca’s current market position in the pharmaceutical industry?

AstraZeneca ranks among the top ten global pharmaceutical companies by revenue. In 2022, it achieved approximately $44 billion in sales, with major contributions from oncology (especially lung and breast cancer therapies), cardiovascular, renal, and metabolic diseases. The company holds leading positions in several therapeutic segments, notably in oncology, with a 13% global market share in this area, second only to Roche. Its geographic footprint extends globally, with the United States contributing roughly 44% of revenue, followed by Europe, Asia, and other regions.

What are AstraZeneca’s core strengths?

Portfolio Diversification

AstraZeneca’s portfolio spans multiple high-growth therapeutic areas. Its oncology segment, driven by blockbuster drugs like Tagrisso, Imfinzi, and Lynparza, accounts for nearly 50% of total sales. The company maintains a strong pipeline with over 80 projects progressing through clinical phases, emphasizing innovation in immuno-oncology, targeted therapies, and respiratory diseases.

R&D Investment

The company allocates approximately 20% of revenues to R&D, enabling continuous pipeline expansion. This level of investment exceeds industry averages and supports sustained innovation. Its R&D centers are located in key markets, including the UK, US, and Sweden.

Strategic Collaborations and Licensing

AstraZeneca has entered multiple partnerships, including co-development agreements with biotech firms and licensing deals with research institutes. These collaborations accelerate drug development and access to novel platforms such as antibody-drug conjugates and gene-based therapies.

Manufacturing Capabilities

The company has advanced manufacturing facilities globally, with significant capacity for biologics and small molecules. This supports reliable supply chains for commercial and clinical needs.

How does AstraZeneca compare with key competitors?

Company	2022 Revenue	Major Focus Areas	Pipeline Highlights	Market Share (Oncology)
Pfizer	$100B	Vaccines, oncology, cardiovascular	mRNA vaccines, cancer immunotherapies	8%
Roche	$63B	Oncology, diagnostics	Cancer immunotherapies, companion diagnostics	17%
Novartis	$51B	Oncology, biosimilars, ophthalmology	CAR-T therapies, biosimilars	9%
AstraZeneca	$44B	Oncology, CVRM, respiratory	PARP inhibitors, targeted lung therapies	13%

AstraZeneca outperforms many competitors in certain oncology niches, notably in targeted lung cancer treatments. Its focus on precision medicine has created a competitive advantage, though it faces stiff competition from Roche’s comprehensive oncology portfolio.

What strategic initiatives shape AstraZeneca’s future?

Focus on Oncology and Rare Diseases

AstraZeneca plans to expand its oncology pipeline, emphasizing personalized medicine. It has prioritized expanding the use of its landmark drugs and developing next-generation therapies for difficult-to-treat cancers.

Investment in Digital and Precision Medicine

The company is integrating digital health tools into clinical development and patient management. It collaborates with tech firms for data analytics, AI-driven drug discovery, and digital therapeutics.

Geographic Expansion

AstraZeneca is increasing market penetration in emerging markets, especially China and India, through tailored pricing strategies and local partnerships. It aims to roughly double revenues from emerging markets by 2025.

Sustainable Innovation and Pricing Strategies

AstraZeneca aligns its R&D and business models with sustainability initiatives, including responsible pricing and access programs to expand drug availability in lower-income regions.

What are the main risks and challenges?

• Patent expirations threaten revenue streams in mature segments.
• Competitive pressures intensify, especially from biologics and biosimilars.
• Regulatory challenges in novel therapies may delay market entry.
• Political and pricing pressures in key markets could affect profitability.

Closing Summary

AstraZeneca maintains strong positioning through diversification, a focused oncology pipeline, and strategic collaborations. Its aggressive R&D investment and expansion into emerging markets support growth despite competitive and regulatory risks.

Key Takeaways

• AstraZeneca is a top-10 global pharma company with a $44 billion revenue in 2022.
• Its oncology segment dominates, with a 13% market share and a pipeline of over 80 projects.
• The company’s strengths include diversified product lines, high R&D spending, strategic alliances, and manufacturing capacity.
• Competition from Roche, Pfizer, and Novartis remains intense, especially on innovative biologics.
• Future growth hinges on expanding oncology and rare disease portfolios, digital health integration, and geographic expansion in emerging markets.

Frequently Asked Questions

1. How does AstraZeneca’s pipeline compare to its competitors?

   • The company has over 80 projects in clinical stages, with significant investments in immuno-oncology, targeted therapies, and genetics-based treatments, positioning it strongly amid industry leaders.

2. What are the key drugs driving AstraZeneca’s current revenue?

   • Tagrisso, Imfinzi, Lynparza, and Farxiga are the main contributors, especially in oncology and cardiovascular/renal areas.

3. How is AstraZeneca addressing patent cliff risks?

   • Through pipeline expansion, lifecycle management of existing drugs, and diversification into rare diseases.

4. What geographies are critical for AstraZeneca’s growth?

   • The US remains dominant, but China and India are strategic for expansion, representing high-growth markets with localized strategies.

5. How does AstraZeneca invest in digital health?

   • It collaborates with tech companies to improve clinical trial efficiency, patient monitoring, and real-world data utilization, integrating AI and data analytics into its research processes.

---

References

[1] AstraZeneca Annual Report 2022. (2022). AstraZeneca.
[2] IQVIA. (2022). Top 20 Global Pharma Companies.
[3] Evaluate Pharma. (2022). World Preview 2022.
[4] Ross, J., & Zhang, Y. (2022). Competitive dynamics in global oncology. Pharma Intelligence.